Trial Profile

Prospective Randomized Multicenter Study in First-Line Treatment of Advanced progredIeNT Follicular And Other IndoleNt and Mantle Cell Lymphomas.

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 26 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bendamustine (Primary) ; Rituximab (Primary) ; Rituximab (Primary)
Indications B-cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Waldenstrom's macroglobulinaemia
Focus Therapeutic Use
Acronyms MAINTAIN; StiL NHL7

Most Recent Events

22 Aug 2024 Planned End Date changed from 1 Apr 2030 to 1 Dec 2024.
22 Aug 2024 Planned primary completion date changed from 1 Apr 2030 to 1 Dec 2024.
17 May 2022 Planned End Date changed from 1 Apr 2022 to 1 Apr 2030.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com